Journal of Market Access & Health Policy
Overview
Journal of Market Access & Health Policy is a scientific journal, published by MDPI since 2013 in English. The journal's country of origin is Switzerland and its primary focus area is public health.
Details
Details
Abbr.
J Mark Access Health Policy
Publisher
MDPI
Start
2013
End
Continuing
e-ISSN
2001-6689
Country
Switzerland
Language
English
Specialty
Public Health
Metrics
Metrics
h-index / Ranks: 10631
29
SJR / Ranks: 6343
698
CiteScore / Ranks: 6529
4.10
Recent Articles
1.
Julian E, Belleman T, Garcia M, Rutten-van Molken M, Doeswijk R, Giuliani R, et al.
J Mark Access Health Policy
. 2025 Feb;
13(1):6.
PMID: 39990187
Background: We examined four potential challenges for the implementation of the European Union (EU) Regulation 2021/2282 on Health Technology Assessment (EU HTAR): interaction with the European Medicines Agency (EMA), expert...
2.
Armstrong H, Petrova A, Wilsdon T, Homoki H, Roediger A
J Mark Access Health Policy
. 2025 Feb;
13(1):2.
PMID: 39990186
Over the past decade, an increasing number of oncology medicines with indications for multiple cancer types have been delivering benefits to patients. To ensure these products reach patients, pricing and...
3.
Tung W, Rankin K, Oris R, Wijesekera A, Wiznia D
J Mark Access Health Policy
. 2025 Feb;
13(1):4.
PMID: 39990185
Introduction: Demographic disparities in musculoskeletal (MSK) health exist in the US. Racial representation in advertising has been shown to influence consumer behavior and buying patterns. Direct-to-consumer advertising that does not...
4.
5.
Lukomska E, Kloc K, Kowalska M, Matjaszek A, Joshi K, Scholz S, et al.
J Mark Access Health Policy
. 2025 Feb;
13(1):7.
PMID: 39990183
Approximately 10-20% of individuals suffering from COVID-19 develop prolonged symptoms known as long COVID or post-COVID condition (LC). This review aimed to assess healthcare resource use (HCRU) and healthcare costs...
6.
Tanner S, Coady R, Lisica A, Falla E, van Engen A
J Mark Access Health Policy
. 2025 Feb;
13(1):3.
PMID: 39990182
The focus of manufacturers preparing for implementation of the EU HTA Regulation (HTAR) in 2025 has understandably been on their market access teams, and how they can be best equipped...
7.
Owusu Achiaw S, Hawkins N, Wu O, Mercer J
J Mark Access Health Policy
. 2025 Jan;
13(1):1.
PMID: 39867672
This study illustrates the utility of a mixed-methods approach in assessing the value of an example novel technology-biosensor-integrated self-reporting arteriovenous grafts (smart AVGs). Currently in preclinical development, the device will...
8.
Ntais C, Kontodimopoulos N, Talias M
J Mark Access Health Policy
. 2024 Dec;
12(4):378-387.
PMID: 39735248
As early as 1978, the World Health Organization set primary healthcare as the basis on which health systems should be built worldwide. However, the health systems of the different countries...
9.
Ntais C, Talias M, Fanourgiakis J, Kontodimopoulos N
J Mark Access Health Policy
. 2024 Dec;
12(4):403-414.
PMID: 39735247
Background: This paper reviews cost containment policies to control pharmaceutical expenditure either by regulating the pharmaceutical industry or targeting the demand side. Methods: The method used was the narrative literature...
10.
Mitakos A, Mpogiatzidis P
J Mark Access Health Policy
. 2024 Dec;
12(4):388-402.
PMID: 39735246
This study evaluates the efficiency of public hospitals in Greece during the COVID-19 epidemic in 2020, using Data Envelopment Analysis (DEA) and the Analytical Hierarchy Process (AHP). Faced with unprecedented...